Ipamorelin Benefits and Side Effects: A Research Guide

Ipamorelin is a pentapeptide growth hormone secretagogue and a selective agonist of the ghrelin (GHS-R1a) receptor. It is the most receptor-selective GHRP in the published literature — the property that makes it the standard reference compound when researchers want pure GH release without the cortisol, prolactin, or appetite confounds of older GHRPs.

This guide summarizes the documented research benefits of ipamorelin, the side-effect profile reported in published trials, and how it compares to other GHRPs (GHRP-2, GHRP-6, hexarelin) and to GHRH analogues.

Research Use Only. This article summarizes published preclinical and clinical literature. It is not medical advice or dosing guidance.

What is ipamorelin?

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (pentapeptide)
• Class: Growth hormone releasing peptide (GHRP) / ghrelin receptor agonist
• Mechanism: Selective GHS-R1a agonism at the pituitary → GH pulse
• Half-life: ~2 hours
• Discovered: Novo Nordisk, late 1990s; reached Phase II human trials for postoperative ileus

Ipamorelin was originally developed by Novo Nordisk and progressed through Phase II human trials for postoperative ileus before the program was discontinued. The clinical-trial data from that program is the largest body of human safety evidence on the compound.

Documented research benefits

1. GH release without cortisol or prolactin elevation The single most replicated finding in the ipamorelin literature is clean GH release. Raun et al. (1998) showed ipamorelin produces a GH response comparable to GHRP-6 and hexarelin but without the significant increases in cortisol, prolactin, or aldosterone that those compounds produce. No other GHRP matches this selectivity.

2. Synergy with GHRH analogues Ipamorelin acts on the ghrelin receptor; sermorelin, tesamorelin, and CJC-1295 act on the GHRH receptor. The two receptor systems are independent, and combining them produces synergistic GH release that exceeds the sum of either alone. The ipamorelin + CJC-1295 (no-DAC) pairing is the most cited stack in GH-secretagogue research.

3. Bone-formation models Animal studies report increased bone mineral content and bone-formation markers (osteocalcin, alkaline phosphatase) with sustained ipamorelin administration — findings consistent with the broader GH/IGF-1 axis literature on bone.

4. Body composition signals Preclinical studies in rodents report lean-mass increases with multi-week ipamorelin administration. Human body-composition data from the discontinued Novo Nordisk program is limited because the trials were targeted at gastric motility rather than composition endpoints.

5. Gastrointestinal motility The Phase II program in postoperative ileus reported accelerated bowel-function recovery, a downstream consequence of ghrelin-receptor agonism in the GI tract. The program did not advance, but the motility finding is well documented.

Side-effect profile in published trials

The Phase II human program is the principal source of safety data. The reported profile is among the mildest of any GH-axis research peptide.

Common adverse events - Injection-site reactions: mild, occasional - Headache: transient, mild - Flushing: uncommon, mild when reported - Mild fatigue or drowsiness after dosing — sporadic

What ipamorelin does not produce The published literature explicitly does not show meaningful elevations in: - Cortisol (a hallmark of GHRP-2, GHRP-6, hexarelin) - Prolactin (same) - Aldosterone (same) - Appetite stimulation (a hallmark of GHRP-6 specifically)

This is the receptor-selectivity argument for ipamorelin in one paragraph — it produces the GH pulse of a GHRP without the off-target endocrine effects.

Long-term human safety The longest published continuous human exposures are from the postoperative-ileus program (short courses, days to weeks). True long-term (multi-year) human safety data is not available — a documented gap researchers should note when designing protocols.

Ipamorelin vs other GHRPs

• Ipamorelin: Most receptor-selective. Cleanest profile. Standard reference.
• GHRP-2: Stronger GH stimulation than ipamorelin but elevates cortisol and prolactin.
• GHRP-6: Comparable GH stimulation; elevates cortisol and prolactin and is a potent appetite stimulant via central pathways.
• Hexarelin: The strongest GH stimulator of the GHRP class; produces the largest cortisol and prolactin elevations; reported pituitary desensitization with chronic high-dose administration.

Researchers select between GHRPs based on what side activity is acceptable — ipamorelin when none is.

Reconstitution and storage notes

Ipamorelin is supplied lyophilized and reconstituted with bacteriostatic water for research use. Refrigerate at 2–8 °C, protect from light, and follow the working-solution window documented on the batch COA. Avoid repeated freeze–thaw cycles.

Bottom line

Ipamorelin is the cleanest GHRP in the published literature: comparable GH release to the older GHRPs without the cortisol, prolactin, aldosterone, or appetite confounds. Paired with a GHRH analog (sermorelin, tesamorelin, or CJC-1295), it produces the most-replicated synergistic GH stack in GH-secretagogue research. Its limitations are duration (short half-life requires multiple daily doses in many protocols) and the absence of long-term human safety data.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. *Eur J Endocrinol*, 1998.
2. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced loss of cortical bone in rats. *Bone*, 2001.
3. Beck DE, et al. Safety and efficacy of ipamorelin for the management of postoperative ileus. *J Gastrointest Surg*, 2014.
4. Greenwood-Van Meerveld B, et al. Preclinical studies of opioid antagonists and GH secretagogues on GI motility. *Curr Opin Pharmacol*, 2014.